Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GuestLogix Inc. stock logo
GXI
GuestLogix
C$0.00
C$0.06
C$0.96
N/AN/A13,293 shsN/A
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Sable Resources Ltd. stock logo
SAE
Sable Resources
C$0.04
C$0.04
C$0.03
C$0.05
C$10.05M1.08205,089 shs2,732 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%+5.63%
Sable Resources Ltd. stock logo
SAE
Sable Resources
0.00%+16.67%-12.50%0.00%-22.22%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
GuestLogix Inc. stock logo
GXI
GuestLogix
N/AN/AN/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/AN/AN/AN/A
Sable Resources Ltd. stock logo
SAE
Sable Resources
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GuestLogix Inc. stock logo
GXI
GuestLogix
0.00
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Sable Resources Ltd. stock logo
SAE
Sable Resources
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GuestLogix Inc. stock logo
GXI
GuestLogix
N/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Sable Resources Ltd. stock logo
SAE
Sable Resources
N/AN/AC$0.02 per share1.44C($0.01) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GuestLogix Inc. stock logo
GXI
GuestLogix
N/AN/A0.00N/AN/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Sable Resources Ltd. stock logo
SAE
Sable Resources
-C$9.09M-C$0.04N/AN/AN/A-481.67%-40.73%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
GuestLogix Inc. stock logo
GXI
GuestLogix
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Sable Resources Ltd. stock logo
SAE
Sable Resources
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GuestLogix Inc. stock logo
GXI
GuestLogix
N/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Sable Resources Ltd. stock logo
SAE
Sable Resources
1.33
0.69
40.33

Institutional Ownership

CompanyInstitutional Ownership
GuestLogix Inc. stock logo
GXI
GuestLogix
N/A
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Sable Resources Ltd. stock logo
SAE
Sable Resources
16.54%

Insider Ownership

CompanyInsider Ownership
GuestLogix Inc. stock logo
GXI
GuestLogix
N/A
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Sable Resources Ltd. stock logo
SAE
Sable Resources
2.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
GuestLogix Inc. stock logo
GXI
GuestLogix
147,000N/AN/ANot Optionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Sable Resources Ltd. stock logo
SAE
Sable Resources
N/A287.06 millionN/ANot Optionable

Recent News About These Companies

Sable Resources (CVE:SAE) Shares Down 14.3% - Here's Why
Sable Resources (CVE:SAE) Stock Price Down 14.3% - What's Next?
Sable Resources (CVE:SAE) Shares Down 14.3% - What's Next?
Sable Oil Wins First Round in Santa Barbara County
Sable Resources Launches New Field Season in Argentina
Stocks in play: Sable Resources Ltd.

Media Sentiment Over Time

Top Headlines

View All Headlines
GuestLogix stock logo

GuestLogix TSE:GXI

GuestLogix Inc. is a retailing and payment technology company. The Company offers a portfolio of hardware, software, content and professional services to travel operators across the world. The Company's segments include GuestLogix Onboard and OpenJaw. Its segments are engaged in providing merchandising, payment and business intelligence technology delivered to the passenger travel industry, both onboard and off-board. The Company focuses on providing retail technology that supports both the travel retail and ancillary revenue programs of the travel industry, such as the sale of onboard food and beverage, duty-free products, onboard entertainment (digital content), seat upgrades and ground ancillaries, such as hotels, car rentals and destination-content. It also serves clients using its retail systems to sell core product offerings, such as airline and rail tickets. Its network spans over 144 countries across the Americas, Europe, the Middle East and Africa (EMEA) and Asia Pacific.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 06/27/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Sable Resources stock logo

Sable Resources CVE:SAE

C$0.04 0.00 (0.00%)
As of 06/27/2025 11:48 AM Eastern

Sable Resources Ltd. engages in the acquisition, exploration, and development of mineral resource properties in Mexico and Argentina. The company explores for gold, silver, copper, lead, zinc, and other deposits. It holds 100% interests in the Don Julio project covering an area of 63,314 hectares; the El Fierro project covering an area of 58,510 hectares; the El Fierrazo project, the Los Pumas project, and the Laspina project located in San Juan Province, Argentina; and the Vinata project and the El Escarpe project located in Mexico. The company also holds interest in the La Poncha property that covers an area of approximately 34,937 hectares located in San Juan, Argentina. In addition, it has an option to acquire a 100% interest in the Perk-Rocky project 10,475 hectares of mineral claims located in Williams Lake, British Columbia. The company was formerly known as Calico Silver Mines Ltd. and changed its name to Sable Resources Ltd. in 1978. Sable Resources Ltd. was founded in 1962 and is based in Vancouver, Canada.